Joshua Zeidner/ X ; Daniel Peters/ X
Jul 13, 2026, 10:49
Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
Joshua Zeidner, Professor of Medicine at The University of North Carolina at Chapel Hill, shared Daniel Peters‘s post on X, adding:
“True privilege to be part of the MD Education AML ALL US Focus 2026 meeting!
Always great to highlight the incredible advances of menin inhibitors and excited to discuss our upcoming RAVEN.
Study for newly diagnosed younger/fit KMT2Ar AML.”
Daniel Peters, Assistant Professor at Medical College of Georgia at Augusta University and Member of the Georgia Cancer Center, shared a post on X:
“One of the many great talks at MD Education AML-ALL focus group.
Joshua Zeidner at UNC Lineberger showing continued, impressive results of Menin-I in NPM1 and KMT2Ar AML and emphasis on frontline combos.
Tip of the iceberg!”
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads